OLMA net incomeQ2 2026-$63.20M
OLMA net income was -$63.20M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$43.78M a year earlier. For the full fiscal 2025 it was -$162.45M, compared with -$129.47M in fiscal 2024.
Olema Pharmaceuticals Inc. (OLMA) financials
For the twelve months ended Jun 30, 2026, Olema Pharmaceuticals Inc. reported -$204.57M of net income.
- Net income, TTM
- -$204.57M
- EPS, diluted, TTM
- -$2.13
- Cash
- $48.60M
- Market cap
- $644.0M
FY2019FY2025
FY2020FY2024
OLMA revenue and earnings growth
OLMA EPSQ2 2026-$0.61
OLMA diluted EPS was -$0.61 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.51 a year earlier. For the full fiscal 2025 it was -$1.87.
OLMA free cash flowQ3 2025-$34.53M
OLMA free cash flow was -$34.53M in fiscal Q3 2025 (ended Sep 30, 2025), compared with -$27.02M a year earlier. For the full fiscal 2024 it was -$104.51M.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Research and development | $157.70M | $124.52M | $86.14M | $82.27M | $51.10M | $13.70M | $3.92M |
| Selling, general and admin | $21.00M | $17.74M | $18.82M | $24.71M | $20.39M | $7.82M | $403.0K |
| Operating income | -$178.70M | -$142.26M | -$104.96M | -$106.99M | -$71.49M | -$21.53M | -$4.32M |
| Interest expense | - | - | - | - | - | $653.0K | - |
| Pre-tax income | -$162.45M | -$129.47M | - | - | - | - | - |
| Income tax | $3.0K | $2.0K | $2.0K | $1.0K | - | - | - |
| Net income | -$162.45M | -$129.47M | -$96.66M | -$104.79M | -$71.10M | -$22.12M | -$4.32M |
| EPS, basic | -$1.87 | -$2.20 | -$2.14 | -$2.62 | -$1.80 | -$3.42 | -$1.66 |
| EPS, diluted | -$1.87 | -$2.20 | -$2.14 | -$2.62 | -$1.80 | -$3.42 | -$1.66 |
| Diluted shares | 87.0M | 58.7M | 45.2M | 40.0M | 39.5M | 7.0M | 2.6M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $48.30M | $139.48M | $68.54M | $23.70M | $13.81M | $338.55M | $68.0K |
| Short-term investments | $457.14M | $294.61M | $193.27M | $180.72M | $273.44M | - | - |
| Current assets | $515.45M | $438.47M | $266.51M | $208.90M | $290.69M | $342.14M | - |
| Total assets | $533.43M | $450.98M | $276.94M | $215.65M | $295.94M | $342.72M | - |
| Current liabilities | $51.80M | $41.76M | $21.62M | $16.55M | $9.02M | $4.58M | - |
| Total liabilities | $54.87M | $42.02M | $23.05M | $18.10M | $11.38M | $4.58M | - |
| Shareholders' equity | $478.56M | $408.96M | $253.90M | $197.55M | $284.57M | $338.14M | -$10.59M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$146.72M | -$104.35M | -$83.73M | -$82.06M | -$50.69M | -$19.87M | -$3.08M |
| Capital expenditures | - | $159.0K | - | $363.0K | $1.57M | $56.0K | - |
| Free cash flow | - | -$104.51M | - | -$82.43M | -$52.27M | -$19.92M | - |
| Investing cash flow | -$155.76M | -$93.53M | -$4.85M | $91.48M | -$275.44M | -$56.0K | - |
| Financing cash flow | $211.30M | $268.82M | $133.41M | $476.0K | $1.39M | $358.40M | - |
| Stock-based compensation | $17.59M | $22.58M | $17.26M | $18.83M | $15.91M | $3.11M | - |
| Depreciation and amortization | $490.0K | $393.0K | $377.0K | $357.0K | $163.0K | $11.0K | $9.0K |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $57.78M | $49.23M | $43.22M | $39.95M | $43.90M | $30.62M | $32.30M | $33.23M | $29.11M | $29.88M | $25.87M | $19.45M |
| Selling, general and admin | $9.39M | $8.75M | $6.86M | $5.93M | $3.96M | $4.25M | $4.47M | $4.39M | $4.42M | $4.46M | $4.54M | $3.89M |
| Operating income | -$67.18M | -$57.99M | -$50.08M | -$45.88M | -$47.86M | -$34.87M | -$36.77M | -$37.62M | -$33.53M | -$34.34M | -$30.42M | -$23.34M |
| Net income | -$63.20M | -$53.09M | -$46.06M | -$42.22M | -$43.78M | -$30.39M | -$33.57M | -$34.55M | -$30.38M | -$30.97M | -$26.77M | -$21.50M |
| EPS, basic | -$0.61 | -$0.52 | -$0.51 | -$0.49 | -$0.51 | -$0.36 | -$0.50 | -$0.60 | -$0.54 | -$0.56 | -$0.47 | -$0.48 |
| EPS, diluted | -$0.61 | -$0.52 | -$0.51 | -$0.49 | -$0.51 | -$0.36 | -$0.50 | -$0.60 | -$0.54 | -$0.56 | -$0.47 | -$0.48 |
| Diluted shares | 104.5M | 102.8M | - | 85.7M | 85.5M | 85.4M | - | 57.3M | 56.3M | 55.6M | - | 45.0M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $48.60M | $52.55M | $48.30M | $35.26M | $52.47M | $50.64M | $139.48M | $35.89M | $16.89M | $33.72M | $68.54M | $117.41M |
| Short-term investments | $412.47M | $452.80M | $457.14M | $293.70M | $309.44M | $342.07M | $294.61M | $178.88M | $222.21M | $215.26M | $193.27M | $159.49M |
| Current assets | $469.88M | $513.23M | $515.45M | $334.33M | $367.73M | $396.66M | $438.47M | $217.99M | $242.19M | $252.09M | $266.51M | $282.01M |
| Total assets | $486.58M | $530.64M | $533.43M | $352.45M | $382.00M | $409.64M | $450.98M | $230.17M | $254.56M | $263.69M | $276.94M | $292.80M |
| Current liabilities | $53.01M | $47.17M | $51.80M | $41.66M | $33.16M | $26.06M | $41.76M | $30.70M | $26.54M | $26.22M | $21.62M | $15.97M |
| Total liabilities | $56.01M | $50.17M | $54.87M | $44.97M | $36.77M | $26.19M | $42.02M | $31.26M | $27.39M | $27.38M | $23.05M | $17.66M |
| Shareholders' equity | $430.56M | $480.48M | $478.56M | $307.49M | $345.24M | $383.45M | $408.96M | $198.91M | $227.16M | $236.32M | $253.90M | $275.13M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$45.90M | -$45.99M | -$38.33M | -$34.53M | -$29.88M | -$43.98M | -$26.28M | -$27.02M | -$27.55M | -$23.50M | -$18.48M | -$22.74M |
| Capital expenditures | - | - | - | $0 | - | - | $0 | $0 | $6.0K | $153.0K | - | - |
| Free cash flow | - | - | - | -$34.53M | - | - | -$26.28M | -$27.02M | -$27.56M | -$23.65M | - | - |
| Investing cash flow | $40.84M | $4.53M | -$162.18M | $17.27M | $34.23M | -$45.08M | -$114.42M | $45.92M | -$4.88M | -$20.14M | -$30.91M | -$25.44M |
| Financing cash flow | $1.11M | $45.70M | $213.55M | $41.0K | -$2.52M | $222.0K | $244.30M | $92.0K | $15.61M | $8.82M | $523.0K | $130.63M |
| Stock-based compensation | $12.90M | $10.15M | $4.27M | $4.25M | $4.69M | $4.38M | $6.32M | $5.63M | $5.72M | $4.91M | $4.35M | $4.11M |
| Depreciation and amortization | $102.0K | $119.0K | $187.0K | $43.0K | $132.0K | $128.0K | $116.0K | $95.0K | $94.0K | $88.0K | $88.0K | $90.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 8.86 | 10.88 | 9.95 | 8.03 | 11.09 | 15.22 | 10.50 | 7.10 | 9.13 | 9.61 | 12.33 | 17.66 |
Source: XBRL data Olema Pharmaceuticals Inc. files with the SEC, latest filing dated Aug 10, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
OLMA peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| OLMA | - | - | -$204.57M | - | $644.0M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
OLMA FAQ
5 questionsIs OLMA profitable?
No. Olema Pharmaceuticals Inc. reported a net loss of $204.57M for the twelve months ended Jun 30, 2026.How much cash and debt does OLMA have?
Olema Pharmaceuticals Inc. reported $48.60M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is OLMA earnings per share?
Diluted earnings per share were -$2.13 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did OLMA last report financial results?
The latest statements here come from Olema Pharmaceuticals Inc.'s 10-Q filed on Aug 10, 2026, covering the period ended Jun 30, 2026.Where does this OLMA financial data come from?
Quantisnow builds these statements from the structured XBRL data Olema Pharmaceuticals Inc. files with the SEC. It is provided for information only and is not investment advice.